netFormulary NHS
Milton Keynes Formulary
Milton Keynes University Hospital NHS Foundation Trust
Milton Keynes Clinical Commissioning Group
Milton Keynes Community Health Services
 Search
 Results

Looking for Adalimumab found 25 matches

Formulary items 4 matches
   
Open monograph to display formulary status BNF Category
  Adalimumab
(Gastroenterology)
Gastro-intestinal system - Cytokine inhibitors - 01.05.03
  Adalimumab
(rheumatology)
Musculoskeletal and joint diseases - Drugs affecting the immune response - 10.01.03
  Restricted Drug Adalimumab
(Ophthalmology)
Eye - Other anti-inflammatory preparations - 11.04.02
  Adalimumab
(Dermatology)
Skin - Drugs affecting the immune response - 13.05.03
 


Linkslink in drug section Link to Drug Section link in subsection Link to document
link in drug section NICE TA187: Crohn’s disease - infliximab and adalimumab  (01.05.03)
link in drug section NICE TA187: Crohns disease - infliximab & adalimumab (01.05.03)
link in drug section NICE TA187: Crohns disease - infliximab & adalimumab (01.05.03)
link in drug section NICE TA187: Crohns disease - infliximab & adalimumab (01.05.03)
link in drug section NICE TA195: Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (10.01.03)
link in drug section NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis  (01.05.03)
link in drug section NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis  (01.05.03)
link in drug section NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis  (01.05.03)
link in drug section NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis (01.05.03)
link in drug section NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis  (01.05.03)
link in drug section NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for JIA (10.01.03)
link in drug section NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (10.01.03)
link in drug section NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (10.01.03)
link in drug section NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (10.01.03)
link in subsection NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab & abatacept in RA (10.01.03)
link in drug section NICE TA392: Adalimumab for treating moderate to severe hidradenitis suppurativa (13.05.03)
link in drug section NICE TA455:Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (13.05.03)
link in drug section NICE TA455:Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (13.05.03)
link in drug section NICE TA460: Adalimumab and dexamethasone for treating non-infectious uveitis (11.04.02)
link in subsection Psoriatic arthritis - etanercept, infliximab and adalimumab (NICE TA199) (10.01.03)
link in drug section Use as per NICE TA460: Adalimumab and dexamethasone for treating non-infectious uveitis (11.04.01)


 

netFormulary